Navigation Links
Allergy & Asthma Network and Avella Specialty Pharmacy Highlight Risks Associated with Latex Allergies and Latex in Healthcare
Date:3/28/2017

VIENNA, Va. and PHOENIX, March 28, 2017 /PRNewswire/ -- Today, Allergy & Asthma Network and Avella Specialty Pharmacy released a new white paper to underscore the significant risks related to latex allergies and the use of latex in healthcare. Specifically, there is substantial confusion as to the meaning of "latex free" in healthcare. In fact, the FDA has urged manufacturers to drop the term "latex free" or a "does not contain latex" claim from labels, because of the challenge to ensure a product is completely devoid of natural rubber latex proteins that cause allergic reactions. According to the FDA, these labeling techniques are not sufficiently specific, not necessarily scientifically accurate, and may be misunderstood and applied too widely.

"Patient and physician safety is our highest priority, and we're pleased to collaborate with Allergy & Asthma Network to shine a spotlight on the risks related to latex allergies and the use of latex in healthcare," said Rebecca Shanahan, CEO of Avella Specialty Pharmacy. "Working in healthcare, it is vitally important to be aware of – and prepare for – all allergies related to the medications and products we use daily. We hope this white paper will equip caregivers with the information they need to ensure their safety and the safety of their patients."

Continue Reading
Latex White Paper Cover
Latex White Paper Cover

"We commend Avella Specialty Pharmacy for its leadership around the important issue of safeguarding against adverse effects related to latex allergies and the use of latex in healthcare," said Tonya Winders, President & CEO of Allergy & Asthma Network. "When working with patients who have latex allergies, healthcare personnel must make efforts to ensure a latex-safe environment and therapy regimen. Allergy & Asthma Network is always looking for new and better ways to promote patient and healthcare professional safety, so we welcome partnerships like this with thoughtful healthcare stakeholders and pharmacies, like Avella."

Co-authors of the new white paper, entitled "Latex Free Claims: A White Paper on the Risks Associated with Latex Allergies and Latex in Healthcare," include latex allergy expert and co-founder of the former American Latex Allergy Association, Sue Lockwood, and Dr. Robert Hamilton, M.S., Ph.D. of Allergy & Asthma Network, along with Avella Specialty Pharmacy's Dr. Eric Sredzinski, Pharm.D., AAHIVP, and Dr. Jenna Vaughn, Pharm.D., PGY1.

To download the white paper, please visit: www.avella.com/latex

About Avella Specialty Pharmacy
Headquartered in Phoenix, Arizona, Avella is a National Accredited Specialty Pharmacy, providing individualized care and support to patients since 1996. Avella's clinical pharmacists and staff members are experts in managing complex disease states and providing compassionate care. The company offers a nationwide distribution service to complement its retail locations. In 2016, Avella was named Specialty Pharmacy of the Year by NASP, a nationally recognized pharmacy trade committee. Inc. Magazine's 2016 list of the 5,000 fastest-growing private companies in the country included Avella for the tenth consecutive year and also recognized Avella as the fastest-growing woman-led company in 2015. In addition, the Arizona Corporate Excellence Awards named Avella Specialty Pharmacy as the second fastest-growing private company based in the state in 2015. For more information, please visit www.avella.com.

About Allergy & Asthma Network
Allergy & Asthma Network is the leading national nonprofit organization dedicated to ending needless death and suffering due to asthma, allergies and related conditions. Allergy & Asthma Network specializes in sharing family-friendly, medically accurate information through its award-winning magazine Allergy & Asthma Today, E-newsletter, AllergyAsthmaNetwork.org and numerous community outreach programs. Follow Allergy & Asthma Network on Facebook and Twitter @AllergyAsthmaHQ. Join the Network at AllergyAsthmaNetwork.org/join.

Media Contact


Maureen Shanahan  

Chris Thatcher

mshanahan@skdknick.com 

cthatcher@5wpr.com

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/allergy--asthma-network-and-avella-specialty-pharmacy-highlight-risks-associated-with-latex-allergies-and-latex-in-healthcare-300430641.html


'/>"/>
SOURCE Avella Specialty Pharmacy
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Allergies: standardisation, regulation and clinical trials breakthroughs with Stallergenes Greer, HAL Allergy, Nestle & LETI
2. Global Allergy Partnering 2010 to 2017
3. CSRAs DynPort Vaccine Company to Help Advance Medical Products for the National Institute of Allergy and Infectious Diseases
4. Five Things to Know About Penicillin Allergy
5. Allergy Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024
6. Tolerability Data for Shires CUVITRU Accepted for Oral Presentation at the American College Of Allergy, Asthma & Immunology Annual Meeting
7. New Hospital Guidelines: Assess Penicillin Allergy To Ensure Optimal Antibiotic Use
8. Penicillin Allergy Is Overstated
9. Indiana Voters Oppose Prescription Requirements for Popular Cold and Allergy Medicines
10. Global Immunoprotein Diagnostic Testing Market 2015-2019 - Infectious Disease, Oncology and Endocrine, Autoimmune & Allergy Testing
11. How Penicillin Allergy Skin Testing Helps Combat A Growing Public Health Threat
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the "Company"), announces that it ... 2017 at the Sheraton Hotel in Toronto, Ontario ... the Company is scheduled to present on Tuesday, May 2 at ... Chairman of the Board, Tony Holler will also attend ... For more details ...
(Date:4/19/2017)... Global Prostate Cancer Therapeutics Market: Overview ... cancer therapeutics market analyzes the current and future ... prostate cancer, launch of promising emerging therapies, as ... drugs & therapeutic biological products, and high growth ... side effects are some of the drivers expected ...
(Date:4/19/2017)... April 19, 2017  New research provides evidence that an ... according to a study released today that will be presented ... in Boston , April 22 to ... treatment of Parkinson,s disease, the oral drug levodopa has long ... longevity. But as the disease progresses, the effects of the ...
Breaking Medicine Technology:
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... Brady ... announced that its B-595 and B-7569 vinyl label materials received ... and warning labels are tested to remain intact and legible, for use on chemical ...
(Date:4/21/2017)... Colo. (PRWEB) , ... April 21, 2017 , ... The ... the Flex House, the next project in the company’s esteemed VISION House demonstration project ... homeowners use exactly the amount of resources they need to live affordably and abundantly ...
(Date:4/21/2017)... ... ... The Hong Kong Polytechnic University (PolyU) launched today the University Research Facility in ... Kong to support teaching, learning and research. It is also the largest research centre ... Kong. , With an area of 620 square metres and more than 50 ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... Alive ... people who wish to overcome their mental health struggles. The Alive team uses ... LeBouthillier says: “Our approach in dealing with a mental health struggle is based on ...
(Date:4/21/2017)... ... April 21, 2017 , ... Metrasens ... of International Trade, the UK’s most prestigious award for business success. The ... of total revenues and has grown by a total of 400% over the ...
Breaking Medicine News(10 mins):